2015
DOI: 10.1016/j.jbspin.2015.02.011
|View full text |Cite
|
Sign up to set email alerts
|

Body Mass Index and response to rituximab in rheumatoid arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
56
1
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 54 publications
(61 citation statements)
references
References 33 publications
3
56
1
1
Order By: Relevance
“…Pers et al did not find a difference in the frequency of remission in obese (41%) compared to overweight (28%) or normal‐weight (46%) BMI categories , but remission was less frequent in obese patients in studies by Iannone et al (17% in obese versus 38% in normal‐weight patients) , Ellerby et al (3% in obese versus 13% in nonobese patients) , and Gremese et al (15% in obese versus 32% in nonobese patients) . Ottaviani et al did not find an association between increasing BMI and remission . Four studies reported the OR for obese subjects achieving remission after adjusting for important confounders .…”
Section: Resultsmentioning
confidence: 92%
“…Pers et al did not find a difference in the frequency of remission in obese (41%) compared to overweight (28%) or normal‐weight (46%) BMI categories , but remission was less frequent in obese patients in studies by Iannone et al (17% in obese versus 38% in normal‐weight patients) , Ellerby et al (3% in obese versus 13% in nonobese patients) , and Gremese et al (15% in obese versus 32% in nonobese patients) . Ottaviani et al did not find an association between increasing BMI and remission . Four studies reported the OR for obese subjects achieving remission after adjusting for important confounders .…”
Section: Resultsmentioning
confidence: 92%
“…A French study found that obese patients were 83% less likely to attain a DAS28 decrease of ≥1.2 after 6 months of follow-up (28). In the Better Anti-Rheumatic Farmacotherapy (BARFOT) study, obesity was associated with 50% lower odds of sustained remission by DAS28 (OR 0.51, 95% CI 0.32–0.84) and worse mHAQ scores compared to non-obese patients (13).…”
Section: Discussionmentioning
confidence: 99%
“…Notable among these studies is an analysis of the BeST trial, showing lower response rates to initial treatment in patients with BMI ≥25 kg/m 2 [30•], and a large Swedish study of DMARD-naïve patients, most treated with methotrexate, in which patients with obesity were significantly less likely to achieve low disease activity at 3 and 6 months [31••]. While small studies have shown no differences in response rates to rituximab or tocilizumab, larger studies are needed to verify these results [35, 36]. At this time, there is no sufficient evidence to suggest that obesity is associated with poor response to a specific class of medications or to support individualizing treatment decisions based on BMI.…”
Section: Obesity Disease Activity and Treatment Responsementioning
confidence: 99%